Vr Adviser, LLC Relmada Therapeutics, Inc. Transaction History

Vr Adviser, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 15, 2023	SELL	$18.3 - $37.02 $13.8 Million - $27.8 Million	-752,016 Reduced 33.13%	1,518,056 $56.2 Million
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $13.8 Million - $27.8 Million	-752,016 Reduced 33.13%	1,518,056 $56.2 Million
Q2 2022 May 15, 2023	BUY	$16.5 - $30.34 $37.5 Million - $68.9 Million	2,270,072 New	2,270,072 $43.1 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $14.9 Million - $23.7 Million	882,352 Added 63.58%	2,270,072 $51.1 Million
Q2 2021 Aug 13, 2021	BUY	$29.55 - $39.15 $15.8 Million - $20.9 Million	534,514 Added 62.65%	1,387,720 $44.4 Million
Q1 2021 May 14, 2021	BUY	$31.52 - $39.28 $5.82 Million - $7.26 Million	184,766 Added 27.64%	853,206 $30 Million
Q2 2020 Aug 14, 2020	SELL	$31.59 - $49.98 $5.51 Million - $8.72 Million	-174,374 Reduced 20.69%	668,440 $29.9 Million
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $20 Million - $42.2 Million	842,814 New	842,814 $28.7 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.